• Home
  • Search Results
  • Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries.

Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries.

International journal of molecular sciences (2021-05-06)
Xiaonan Zhang, Mihir Shetty, Valentino Clemente, Stig Linder, Martina Bazzaro
ABSTRACT

Ovarian clear cell carcinoma (OCCC) is a rare but chemorefractory tumor. About 50% of all OCCC patients have inactivating mutations of ARID1A, a member of the SWI/SNF chromatin-remodeling complex. Members of the SWI/SNF remodeling have emerged as regulators of the energetic metabolism of mammalian cells; however, the role of ARID1A as a modulator of the mitochondrial metabolism in OCCCs is yet to be defined. Here, we show that ARID1A loss results in increased mitochondrial metabolism and renders ARID1A-mutated cells increasingly and selectively dependent on it. The increase in mitochondrial activity following ARID1A loss is associated with increase in c-Myc expression and increased mitochondrial number and reduction of their size consistent with a higher mitochondrial cristae/outer membrane ratio. Significantly, preclinical testing of the complex I mitochondrial inhibitor IACS-010759 showed it extends overall survival in a preclinical model of ARID1A-mutated OCCC. These findings provide for the targeting mitochondrial activity in ARID1A-mutated OCCCs.

MATERIALS
Product Number
Brand
Product Description

Roche
ATP Bioluminescence Assay Kit HS II, sufficient for 500 assays (tubes), sufficient for 1,000 assays (microplate), kit of 1 (4 components), suitable for detection
Sigma-Aldrich
Mitochondria Isolation Kit, sufficient for 50 applications (2-5 x 107 cells), isolation of enriched mitochondrial fraction from cells